Accueil   Diary - News   All news Tollys appoints Philippe Goupit as chairman of the board

Tollys appoints Philippe Goupit as chairman of the board

With more than 35 years experience in the pharmaceutical
industry and biotech, Philippe Goupit will lead Tollys’ plans for growth

 

Lyon, France, February 1, 2021 – Tollys, a biopharmaceutical company developing TL532, the first synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, today announces the appointment of Philippe Goupit as chairman of the board of directors. This appointment comes at an important time for Tollys, with the active planning of its next fundraising to support the first phase I clinical trials, which are expected to start in 2022.


Jacques-François Martin, co-founder and former chairman of the board said: “We are thrilled to appoint Philippe Goupit as chairman of the board. His valuable experience and skills will support our ambitions and help strengthen our board of directors at a key stage.”

 

Read the press release